The fab fragment of a novel anti-GPVI monoclonal antibody, OM4, reduces in vivo thrombosis without bleeding risk in rats

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 27, Issue 5, 2007, Pages 1199-1205

  Li, Haiquan ^a   Lockyer, Simon ^a   Concepcion, Alice ^a   Gong, Xiaoqi ^a   Takizawa, Hisao ^a   Guertin, Moe ^a   Matsumoto, Yutaka ^a   Kambayashi, Junichi ^a   Tandon, Narendra N ^a   Liu, Yongge ^a  

^a OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

Author keywords

Aggregation; Bleeding time; Glycoprotein VI; Platelet; Thrombosis

Indexed keywords

ABCIXIMAB; ADENOSINE DIPHOSPHATE; ARACHIDONIC ACID; COLLAGEN; GLYCOPROTEIN; GLYCOPROTEIN 6; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY OM 4; OM 4; UNCLASSIFIED DRUG;

ACUTE DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY BLOOD FLOW; ARTICLE; BLEEDING; BLEEDING TIME; CAROTID ARTERY; CAROTID ARTERY INJURY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CONVALESCENCE; DOWN REGULATION; DRUG BINDING; DRUG BLOOD LEVEL; EX VIVO STUDY; EXPERIMENTAL MODEL; IC 50; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; RAT; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTOPENIA; THROMBOSIS;

ANIMALS; ANTIBODIES, MONOCLONAL; BLEEDING TIME; BLOTTING, WESTERN; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HEMORRHAGE; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN G; INCIDENCE; INJECTIONS, INTRAVENOUS; PLATELET AGGREGATION; PLATELET COUNT; PLATELET MEMBRANE GLYCOPROTEINS; RATS; RISK FACTORS; THROMBOSIS;

EID: 34247398257     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.107.140590     Document Type: Article

References (30)

1. Jackson SP, Schoenwaelder SM. Antiplatelet therapy: in search of the 'magic bullet'. Nat Rev Drug Discov. 2003;2:775-789.
2. Lecut C, Feeney LA, Kingsbury G, Hopkins J, Lanza F, Gachet C, Villeval JL, Jandrot-Perrus M. Human platelet glycoprotein VI function is antagonized by monoclonal antibody-derived Fab fragments. J Thromb Haemost. 2003;1:2653-2662.
3. Nieswandt B, Schulte V, Bergmeier W, Mokhtari-Nejad R, Rackebrandt K, Cazenave JP, Ohlmann P, Gachet C, Zirngibl H. Long-term antithrombotic protection by in vivo depletion of platelet glycoprotein VI in mice. J Exp Med. 2001;193:459-469.
4. Gibbins JM. Platelet adhesion signalling and the regulation of thrombus formation. J Cell Sci. 2004;117:3415-3425.
5. Nieswandt B, Watson SP. Platelet-collagen interaction: is GPVI the central receptor? Blood. 2003;102:449-461.
6. Sugiyama T, Okuma M, Ushikubi F, Sensaki S, Kanaji K, Uchino H. A novel platelet aggregating factor found in a patient with defective collagen-induced platelet aggregation and autoimmune thrombocytopenia. Blood. 69:1712-1720.
7. Moroi M, Jung SM, Okuma M, Shinmyozu K. A patient with platelets deficient in glycoprotein VI that lack both collagen-induced aggregation and adhesion. J Clin Invest. 1989;84:1440-1445.
8. Ryo R, Yoshida A, Sugano W, Yasunaga M, Nakayama K, Saigo K, Adachi M, Yamaguchi N, Okuma M. Deficiency of P62, a putative collagen receptor, in platelets from a patient with defective collagen-induced platelet aggregation. Am J Hematol. 1992;39:25-31.
9. Arai M, Yamamoto N, Moroi M, Akamatsu N, Fukutake K, Tanoue K. Platelets with 10% of the normal amount of glycoprotein VI have an impaired response to collagen that results in a mild bleeding tendency. Br J Haematol. 1995;89:124-130.
10. Kato K, Kanaji T, Russell S, Kunicki TJ, Furihata K, Kanaji S, Marchese P, Reininger A, Ruggeri ZM, Ware J. The contribution of glycoprotein VI to stable platelet adhesion and thrombus formation illustrated by targeted gene deletion. Blood. 2003;102:1701-1707.
11. Boylan B, Chen H, Rathore V, Paddock C, Salacz M, Friedman KD, Curtis BR, Stapleton M, Newman DK, Kahn ML, Newman PJ. Anti-GPVI-associated ITP: an acquired platelet disorder caused by autoantibody-mediated clearance of the GPVI/FcRgamma-chain complex from the human platelet surface. Blood. 2004;104:1350-1355.
12. Lockyer S, Okuyama K, Begum S, Le S, Sun B, Watanabe T, Matsumoto Y, Yoshitake M, Kambayashi J, Tandon NN. GPVI-deficient mice lack collagen responses and are protected against experimentally induced pulmonary thromboembolism. Thromb Res. 2006;118:371-380.
13. Qian MD, Villeval JL, Xiong X, Jandrot-Perrus M, Nagashima K, Tonra J, McDonald K, Goodearl A, Gill D. Anti GPVI human antibodies neutralizing collagen-induced platelet aggregation isolated from a combinatorial phage display library. Hum Antibodies. 2002;11:97-105.
14. Moroi M, Mizuguchi J, Kawashima S, Nagamatsu M, Miura Y, Nakagaki T, Ito K, Jung SM. A new monoclonal antibody, mAb 204-11, that influences the binding of platelet GPVI to fibrous collagen. Thromb Haemost. 2003;89:996-1003.
15. Smethurst PA, Joutsi-Korhonen L, O'Connor MN, Wilson E, Jennings NS, Garner SF, Zhang Y, Knight CG, Dafforn TR, Buckle A, IJsseldijk MJ, De Groot PG, Watkins NA, Farndale RW, Ouwehand WH. Identification of the primary collagen-binding surface on human glycoprotein VI by site-directed mutagenesis and by a blocking phage antibody. Blood. 2004;103:903-911.
16. Schulte V, Rabie T, Prostredna M, Aktas B, Gruner S, Nieswandt B. Targeting of the collagen-binding site on glycoprotein VI is not essential for in vivo depletion of the receptor. Blood. 2003;101:3948-3952.
17. Massberg S, Konrad I, Bultmann A, Schulz C, Munch G, Peluso M, Lorenz M, Schneider S, Besta F, Muller I, Hu B, Langer H, Kremmer E, Rudelius M, Heinzmann U, Ungerer M, Gawaz M. Soluble glycoprotein VI dimer inhibits platelet adhesion and aggregation to the injured vessel wall in vivo. FASEB J. 2004;18:397-399.
18. Matsumoto Y, Takizawa H, Gong X, Le S, Lockyer S, Okuyama K, Tanaka M, Yoshitake M, Tandon NN, Kambayashi J. Highly potent anti-human GPVI monoclonal antibodies derived from GPVI knockout mouse immunization. Thromb Res. 2007;119:319-329.
19. Matsumoto Y, Takizawa H, Nakama K, Gong X, Yamada Y, Tandon NN, Kambayashi J. Ex vivo evaluation of anti-GPVI antibody in Cynomolgus monkeys: Dissociation between anti-platelet aggregatory effect and bleeding time. Thromb Haemost. 2006;96:167-175.
20. Bush LR, Shebuski RJ. In vivo models of arterial thrombosis and thrombolysis. FASEB J. 1990;4:3087-3098.
21. Folts J. An in vivo model of experimental arterial stenosis, intimal damage, and periodic thrombosis. Circulation. 1991;83(6 Suppl):IV3-IV14.
22. Kojima H, Moroi M, Jung SM, Goto S, Tamura N, Kozuma Y, Suzukawa K, Nagasawa T. Characterization of a patient with glycoprotein (GP) VI deficiency possessing neither anti-GPVI autoantibody nor genetic aberration. J Thromb Haemost. 2006;4:2433-2442.
23. Boylan B, Berndt MC, Kahn ML, Newman PJ. Activation-independent, antibody-mediated removal of GPVI from circulating human platelets: development of a novel NOD/SCID mouse model to evaluate the in vivo effectiveness of anti-human platelet agents. Blood. 2006;108:908-914.
24. Massberg S, Gawaz M, Gruner S, Schulte V, Konrad I, Zohlnhafer D, Heinzmann U, Nieswandt B. A crucial role of glycoprotein VI for platelet recruitment to the injured arterial wall in vivo. J Exp Med. 2003;197:41-49.
25. Gruner S, Prostredna M, Koch M, Miura Y, Schulte V, Jung SM, Moroi M, Nieswandt B. Relative antithrombotic effect of soluble GPVI dimer compared with anti-GPVI antibodies in mice. Blood. 2005;105:1492-1499.
26. Sassoli PM, Emmell EL, Tam SH, Trikha M, Zhou Z, Jordan RE, Nakada MT. 7E3 F(ab′)2, an effective antagonist of rat alphaIIbbeta3 and alphavbeta3, blocks in vivo thrombus formation and in vitro angiogenesis. Thromb Haemost. 2001;85:896-902.
27. Sudo Y, Kilgore KS, Lucchesi BR. Monoclonal antibody [7E3 F(ab′)2] prevents arterial but not venous rethrombosis. J Cardiovasc Pharmacol. 1995;26:241-250.
28. Bazin-Redureau MI, Renard CB, Scherrmann JM. Pharmacokinetics of heterologous and homologous immunoglobulin G, F(ab′)2 and Fab after intravenous administration in the rat. J Pharm Pharmacol. 1997;49:277-281.
29. Mangin P, Yap CL, Nonne C, Sturgeon SA, Goncalves I, Yuan Y, Schoenwaelder SM, Wright CE, Lanza F, Jackson SP. Thrombin overcomes the thrombosis defect associated with platelet GPVI/FcRgamma deficiency. Blood. 2006;107:4346-4353.
30. Dubois C, Panicot-Dubois L, Merrill-Skoloff G, Furie B, Furie BC. Glycoprotein VI-dependent and -independent pathways of thrombus formation in vivo. Blood. 2006;107:3902-3906.